Johnson & Johnson/AbbVie Inc.’s Imbruvica has emerged on top once again in the transitioning chronic lymphocytic leukemia market, leaving Gilead Sciences Inc.’s already flagging Zydelig to struggle with some new safety issues, but Roche/AbbVie Inc.’s investigational BCL-2 inhibitor venetoclax looks to be a strong contender.
This year’s American Society of Hematology annual meeting, held Dec. 5-8 in Orlando, Fla., provided a platform for established CLL drugs to expand and new drugs to make their mark.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?